As of 2025-11-20, the Relative Valuation of Oramed Pharmaceuticals Inc (ORMP) is (9.47) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.50 USD, the upside of Oramed Pharmaceuticals Inc based on Relative Valuation is -479.7%.
The range of the Relative Valuation is (8.89) - (10.02) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.0x | 15.0x |
| Forward P/E multiples | 15.1x - 20.7x | 17.2x |
| Fair Price | (8.89) - (10.02) | (9.47) |
| Upside | -456.2% - -501.5% | -479.7% |
| Date | P/E |
| 2025-11-19 | -4.23 |
| 2025-11-18 | -4.23 |
| 2025-11-17 | -3.97 |
| 2025-11-14 | -3.95 |
| 2025-11-13 | -4.07 |
| 2025-11-12 | -4.19 |
| 2025-11-11 | -4.11 |
| 2025-11-10 | -3.87 |
| 2025-11-07 | -3.72 |
| 2025-11-06 | -3.73 |
| 2025-11-05 | -3.80 |
| 2025-11-04 | -3.87 |
| 2025-11-03 | -4.00 |
| 2025-10-31 | -4.06 |
| 2025-10-30 | -4.07 |
| 2025-10-29 | -4.02 |
| 2025-10-28 | -4.00 |
| 2025-10-27 | -4.02 |
| 2025-10-24 | -4.06 |
| 2025-10-23 | -4.02 |
| 2025-10-22 | -3.89 |
| 2025-10-21 | -3.97 |
| 2025-10-20 | -3.89 |
| 2025-10-17 | -3.78 |
| 2025-10-16 | -3.85 |
| 2025-10-15 | -3.85 |
| 2025-10-14 | -4.00 |
| 2025-10-13 | -4.09 |
| 2025-10-10 | -4.09 |
| 2025-10-09 | -4.02 |
| 2025-10-08 | -4.06 |
| 2025-10-07 | -4.21 |
| 2025-10-06 | -4.16 |
| 2025-10-03 | -4.14 |
| 2025-10-02 | -4.27 |
| 2025-10-01 | -4.33 |
| 2025-09-30 | -4.48 |
| 2025-09-29 | -4.58 |
| 2025-09-26 | -4.09 |
| 2025-09-25 | -4.07 |
| 2025-09-24 | -4.07 |
| 2025-09-23 | -4.23 |
| 2025-09-22 | -4.19 |
| 2025-09-19 | -3.97 |
| 2025-09-18 | -4.14 |
| 2025-09-17 | -3.85 |
| 2025-09-16 | -3.89 |
| 2025-09-15 | -3.94 |
| 2025-09-12 | -4.09 |
| 2025-09-11 | -4.12 |